Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, which will prove as the best move. That move in itself is of more value than given credit....
There is no reason for GM to go anywhere. If anything they will gain 20-25% stake now in NKLA. FINALLY BACK IN HERE 17.70
Added .7.... time to close offering and move up. Sign a distributor in the US
Bought more as well .74.... but my average is in the .8s still. Have built a decent position here... love these bottom prices!! Monday should bring the closing of the offering and do believe shares rise..... 20k shares but can add more on continued set back.... looked like buying started pretty good last 30 min Friday!
BOUGHT MORE!
NAOV.... CBAT did great... was happy with 250% keeping much smaller stake but yes added to NAOV 11 million shares offering closing, FDA Nod to enter USA
I came in for 1.06 got out 3.7.... Got much smaller position at 2.15... ill see what happens but have limited my position significantly and added to NAOV... 11 million shares FDA approval offering to close today or soon... GLTY
bought more .81... 0 volume as well... everything waiting on the offering closing?
Good call on that 85s and 90.... close the offering today and move higher
Still a great buy .91 here. Surprised!!! Added more!! No scam here wainwright ups to 1.8 million... scam ?.. Peter us lol
Yes... probably closer to 11.3 million shares here now and soon to be another 5 million at least on SPI.... AMZING MOVE
Only have 7k shares .965 average.... if .85 and .9 come along will add more....
Yes. I’m fine buying .95
Yes at 1.00$. Getting under that is a discount at this point.... picked up .98
GREAT CALL?? Selling the open was not a good call,,,,,
HAHA.... How many times have you written sell the open and thank me later? maybe just others because i read the same things here last week and week prior!
KODK gunna KEEP the fire BURNING!
This will be a must own but have lots of time. Looks like they look to Aquire by Oct 2021.
VXRT NEWSS MUST BE
Good one
Yes.... 12++... stake from SHAW. NO LAWS BROKEN. loan coming and manufacturing needed!!
How many shares did theY sell blindly this time?? 55 million in 6 weeks I’m sure more got pumped out here.
Yes there is I have posted summary below
The studies summarized within this section demonstrated that oral administration of VXA-G2.4-NS could elicit substantial antibody responses to norovirus VP1 by ELISA in mice and ferrets. Local immunity could play a very important role preventing infection and disease, and SIgA would likely be the most effective gut immune response to combat a gut pathogen such as norovirus. These studies demonstrate that VXA-G2.4-NS oral delivery generated intestinal SIgA response and superior levels of SIgA to VP1 injectable protein vaccine.
An oral formulation could greatly facilitate vaccine administration, particularly during a pandemic when rapid distribution is needed. During the 2009 H1N1 pandemic, when vaccine was in short supply, individual county health departments in California had to have a plan for distribution. In Los Angeles County, approximately 60 points of distribution (PODs) were tasked to administer the vaccine. Approximately 247 persons per hour lined up, and the rate of immunization was approximately 239 person per hour at each POD (Saha et al. Emerging infectious diseases 2014; 20(4): 590-5). For the PODs in Los Angeles County, this translated to 143,000 people per day. In a city of 9 million, assuming supplies or qualified personnel were not in short supply, it would take more than 60 days to complete an immunization campaign. As an alternative, if the H1N1 pandemic vaccine was delivered by US mail and self-administered by tablet, all 9 million subjects could be immunized within a single day without people having to stand in line, and risking exposure to the growing outbreak. While there are regulatory hurdles to overcome, our tablet vaccine appears to be stable at room temperature for greater than 270 days and can tolerate short-term excursions at higher temperatures (G. Trager, un- published data), which should make this approach technically feasible.
[0222] In summary, oral influenza vaccine based on rAd administration can elicit antibody responses to influenza in greater than 90% of subjects. While this is an early clinical stage study and several studies will need to be completed that address issues such as interference and repeated seasonal use, these results look encouraging for safety and immunogenicity.
Vaxart has conducted preclinical studies to determine the immunogenic potential of VXA-RSV-f in mice and cotton rats. These studies showed that vaccination with VXA-RSV-f elicited substantial systemic serum IgG responses in test animals.
[0181] As described
The primary objective of the immunogenicity studies of the RSV vaccine candidate VXA-RSV-f was to demon-
strate that vector construct could elicit antibody responses in mice and cotton rats, and that the adaptive immune responses generated did not lead to enhanced RSV disease such as that known to occur with the formalin inactivated RSV vaccine. Further, studies were performed in animals to demonstrate the value of the adjuvant for inducing antigen specific immune enhancement.
Table 5 Nonclinical Pharmacolog
Mice (6 females/group) were immunized with VXA-RSV-f using three different routes of delivery in order to determine whether the construct was immunogenic. Animals were immunized with 1x108 IU on weeks 0 and 3 using three different routes of delivery (intranasal, intramuscular, and oral). Antibody titers to RSV were measured on week 7. Results show that both the i.n. and i.m. routes of delivery were potent at eliciting antibody responses, and that oral administration was able to elicit some immunity but was not as potent in mice as the other two routes of delivery
Lungs and nasal passages were harvested 5 days later and analyzed for the ability of the vaccines to protect against RSV replication and disease in cotton rat tissue. Immunization with the VXA- RSV-f vaccine provided complete protection against RSV replication in both lungs and the nose, whereas the formalin inactivated vaccine (FI-RSV) and adjuvant alone (Ad-Adj) groups provided no protection against
There were no serious adverse events reported in the study.
Agreee! Even for the current price KODK IS WELL WORTH THE GAMBLE LET ALONE THE INVESTMENT...
KODK will get the loan. Only a matter of when.
Just don’t like seeing 55 million additional shares in a months time.
Short to zero and pay back zero... keep all proceeds never invest a dime and make millions. SRNE KEEPS SELLING SHARES PRICE IS GOING TO BE 4$ soon
Didnt catch it but sounds uneventful. Is there more to come?
Finally more action in the GREEN.... Will it last this time? FDA GIVES THE NOD!
Vaxart CAN and WILL fix VACCINE concerns about shipments, storage and transportation. VXRT$$$
2.50 calls still getting gobbled for DEC and JAN
CODX great week! I am expecting a reaction in PTE as well at conference! Established a sizeable position today. Thinking the expansion will mean great things...
"We look forward to growing this collaboration with Co-Diagnostics to potentially include additional molecular diagnostic testing opportunities in the future."
Testing = necessity
Necessity = $$$
Getting close to that time again...
Great price... CODX $$$ company will start becoming extremely cash rich!!! Big conference next week
Bunch of criminals
Adjustment. For so long as the warrants remain outstanding, the exercise price and number of shares of Common Stock issuable upon exercise of the warrant is subject to adjustment as follows: (a) as the Company’s board of directors deems appropriate, or (b) upon subdivision (by stock spilt, stock dividend, recapitalization, or otherwise) or combination (by reverse stock split or otherwise) of shares of Common Stock. The Company has filed notice of its 2018 Annual Meeting of Shareholders which will take place December 6, 2018 for shareholders of record on October 12, 2018; on the agenda is a vote to approve a reverse split of the issued and outstanding common stock of the Company.
I Thought they stated the warrants would remain unchanged. Even with the reverse split. If the terms of the warrants changed when the vote went through the warrants and your original investment would be fully refundable?
Participants in the September 14-16 conference, which will be held virtually, include public companies, industry executives, business development executives, institutional investors, and more
Would rather have my shares here and now.
Would love to see CRL AND CODX get a chunk of the 72 million in contracts taken from HONU